Research Results
Beta Version
Use the search bar below to find studies, or apply one or more filters to narrow your results. See our list of keywords to guide your search.
Search by keyword
Select
Select
- All Risk Factors
- Air Pollution
- Alcohol
- Antimicrobials
- Artificial sweeteners
- Bisphenols
- Body Weight
- Breast Density
- Chemical Mixtures
- Chemicals in products
- Cleaning Products
- Diet
- Exercise
- Family History
- Furniture & Electronics
- Genetics
- Gut Health
- Hair Dye
- Hormones
- Inflammation
- Job
- Light at night
- Metals
- Neighborhood
- Night Shift Work
- Noise
- Non-stick Pans & Waterproof Gear
- Oral Contraceptives
- PAHs
- Parabens
- PCBs
- Personal Care Products
- Pesticides
- PFAS
- Pharmaceuticals
- Place-based
- Plastic
- Pregnancy & Breastfeeding
- Processed Food
- Puberty Age
- Race/Ethnicity
- Radiation
- Red meat
- Scented Products & Soft Plastic
- Sleeping Patterns
- Soda
- Stress
- Sugar
- Sunscreen
- Tobacco
- Vitamin D
Select
Select
Select
Select
Select the Chemical Agents
- All Chemical Agents
- 1,1,2,2-TCA
- 1,3-Butadiene
- Acrolein
- Aldrin
- Alkylphenols
- Antimicrobials
- Antimicrobials: QACs, Triclosan, Triclocarban
- Aromatic Amines
- Arsenic
- Artificial Sweeteners
- Atrazine
- Benzene
- Bisphenols
- Cadmium
- Chlordane
- Chlorpyrifos
- DDT
- Dibutyl Phthalate
- Dichlorvos
- Dieldrin
- Dioxins
- ell/
- Ethanol (alcohol)
- Ethyl Benzene
- Ethylene Oxide
- Flame Retardants
- Food
- Formaldehyde
- Glyphosate
- Heptachlor
- Hormones
- Insulin
- Lead
- Light at Night
- Mercury
- Metals
- Methoxyclor
- Naphthalene
- Night Shift Work
- Nitrogen Dioxide
- Noise
- Oral Contraceptives
- Organochlorine Pesticides
- Organophosphate Pesticides
- Ozone
- PAHs
- Parabens
- Particulate Matter
- PCBs
- Pesticides
- PFAS
- Phenols
- Phthalates
- Processed Food
- PVC
- Radiation: Ionizing
- Radiation: Non-Ionizing
- Soda
- Stress
- Sugar
- Tobacco
- Toluene
- Trichloroethylene
- Triclosan
- Ultraviolet Radiation
- UV Filters
- Vinyl Chloride
Select the Study Tags
Sort By
- Relevance
- Title (A to Z)
- Title (Z to A)
- Publication Year (Ascending)
- Publication Year (Descending)
- Authors (A to Z)
- Authors (Z to A)
2019
J Clin Oncl
This large-scale Danish nationwide study followed 1.12 million women over nearly 10 million woman-years to examine the relationship between phthalate exposure from prescription medications and breast cancer risk. The researchers tracked phthalate exposure by linking a database of drug ingredients with prescription records, finding that most phthalate exposures were not associated with increased breast cancer risk. However, high-level cumulative exposure to dibutyl phthalate (≥10,000 mg) was associated with approximately double the risk of estrogen receptor-positive breast cancer, consistent with laboratory evidence showing this compound has estrogenic effects. The study concludes that women should avoid high-level dibutyl phthalate exposure, particularly through long-term use of pharmaceuticals containing this compound, though lower exposure levels did not increase breast cancer risk.
2025
Front Toxicol
The study examined the estrogenic and anti-estrogenic effects of three endocrine disruptors: Bisphenol A (BPA), which mimics estrogen, 17 -Estradiol (E2), the endogenous nuclear estrogen receptor ligand, and Fulvestrant (FUL), a drug that interferes with proper estrogen function. The experiment measured the influence of the endocrine disruptors in vitro using 2D and 3D T47D and MCF7 cells, which are estrogen receptor-positive human breast cancer cells. The study results concluded that E2 and BPA increased the expression of the estrogen-regulated marker pS2 and decreased TGF 3. Meanwhile, FUL inhibited E2 and BPA’s expression of the estrogen-regulated markers, meaning FUL reversed the effects of the other two endocrine disruptors.
2024
Breast Cancer Res
A nested case-control study within the French E3N-Generations cohort examined 523 breast cancer cases and 523 matched controls to investigate whether thirteen metabolic health biomarkers mediate the relationship between exposure to three air pollutants (nitrogen dioxide, PCB153, and benzo[a]pyrene) and breast cancer risk. The study found that benzo[a]pyrene exposure was associated with a significant 2.32-fold increased breast cancer risk (highest vs. lowest quartile), PCB153 showed inconsistent positive associations, and nitrogen dioxide showed no association; among biomarkers, estradiol was associated with increased breast cancer risk (OR = 1.22 per SD). Four-way decomposition mediation analysis revealed suggestive evidence that albumin, HDL and LDL cholesterol, parathormone, and estradiol may partially mediate the associations between all three pollutants and breast cancer risk, though findings were limited by statistical power. These results provide preliminary mechanistic insights suggesting that air pollutants may influence breast cancer risk through alterations in metabolic biomarkers—particularly lipid metabolism and hormone regulation—though larger studies are needed to confirm these pathways and establish the clinical significance of these mediating effects in the relationship between environmental exposures and breast cancer development.
2024
Breast Cancer Res Treat
A meta-analysis of 10 randomized controlled trials including 14,282 participants and 591 breast cancers found that estrogen-alone hormone therapy was associated with a significant 23% reduction in breast cancer incidence (3.6% vs 4.7% in estrogen vs placebo groups, RR 0.77, 95% CI 0.65-0.91, P=0.002). This finding was driven primarily by the large Women’s Health Initiative trial but was supported by nine smaller trials showing similar directional effects, with estradiol formulations showing a 37% non-significant risk reduction. These results from randomized trials contradict findings from observational cohort studies and challenge conventional wisdom about hormone therapy and breast cancer, suggesting that estrogen-alone therapy (in women without a uterus) may actually protect against breast cancer rather than increase risk—a finding with important implications for counseling postmenopausal women about menopausal hormone therapy decisions.
2024
Br J Cancer
A large prospective study of 1,275,783 women aged 45+ years followed for a median 12.7 years from 2004 examined associations between menopausal hormone therapy (HT) types and breast cancer risk, finding that oral estrogen combined with daily progestin carried the highest risk (HR=2.42; 95% CI: 2.31-2.54), with drug-specific hazard ratios ranging from Cliovelle® (HR=1.63) to Kliogest® (HR=2.67), while vaginal estradiol showed no association with breast cancer. The associations varied substantially by molecular subtype (stronger for luminal A: HR=1.97 vs. other subtypes), detection mode (stronger for interval-detected: HR=2.00 vs. screen-detected cancers: HR=1.33 in women 50-71), and BMI (decreasing hazard ratios with increasing BMI). These contemporary findings confirm that oral and transdermal HT use increases breast cancer risk with important variation by specific formulations, administration routes, tumor characteristics, and patient factors, providing critical updated evidence for clinical decision-making about menopausal hormone therapy use and emphasizing the need for individualized risk-benefit assessment accounting for HT type, body weight, and cancer screening participation.
2024
Environ Health Perspect
Researchers analyzed 279 chemicals known to cause mammary tumors in rodents and identified 642 additional chemicals that activate estrogen or progesterone signaling, finding that tumor-causing chemicals were significantly more likely to stimulate hormone production, activate estrogen receptors, or damage DNA—characteristics that likely increase breast cancer risk in humans. The study found that more mammary carcinogens worked by increasing hormone production than by directly activating estrogen receptors, with chemicals showing stronger hormone-disrupting effects being most likely to cause tumors, demonstrating a clear dose-response relationship. These findings suggest that hundreds of chemicals currently in use may pose unrecognized breast cancer risks and should not be assumed safe without specific testing for breast effects, with the strongest evidence chemicals prioritized for exposure reduction and improved testing methods needed to identify additional hazardous substances. The research provides a framework for identifying and regulating chemicals that may contribute to breast cancer through hormone disruption and genetic damage—mechanisms supported by both animal and human studies.
2023
Chemosphere
A community-based intervention study (REDUXE) examined the effects of discontinuing paraben and phthalate-containing personal care products over 28 days by collecting paired fine needle aspirates of breast tissue from healthy volunteers before and after intervention, finding striking reversal of cancer-associated phenotypes including PI3K-AKT/mTOR pathway alterations, autophagy, and apoptotic signaling networks, along with significant reductions in urinary paraben and phthalate metabolites. Post-intervention breast tissue showed “normalizing” changes in estrogen-modulated gene expression pathways, estrogen receptor alpha:beta ratios, and cell cycle S-phase fraction when treated with 17β-estradiol in vitro, demonstrating functional improvement in cellular responses. This paradigm-shifting study reveals that persistent exposure to xenoestrogens from daily-use personal care products produces unfavorable pro-carcinogenic cellular changes in human breast tissue that can be reversed through short-term avoidance, suggesting that reducing xenoestrogen exposure from consumer products may suppress cancer-promoting phenotypes and represents a viable approach for breast cancer prevention.
2021
BMC Complement Med Ther
This study focused on the effect that tartrazine (E102), a common yellow food dye, had on the progression of breast cancer in rats that were exposed to 7,12-Dimethylbenz(a)anthracene (DMBA), a polycyclic aromatic hydrocarbons (PAH) that is widely known for its carcinogenicity. The researchers discovered that tartrazine accelerated the development and growth of tumors in the rats with 100% of rats having early incidents of breast cancer when exposed to both DMBA and tartrazin, and only 80% having early incidence when exposed to DMBA alone. The authors also hypothesized that tartrazine could cause oxidative stress, leading to DNA damage by producing Reactive Oxygen Species. These results may apply to humans as well, and raise concerns about the safety of prolonged or high-dose exposure to synthetic food dyes like tartrazine, especially in individuals who may already have other risk factors for cancer.
2020
Int J Cancer
A nested case-control study within a large European cohort of 430 breast cancer cases and 645 controls found that while alcohol consumption was associated with a 17% increased overall breast cancer risk (36% for ER-positive tumors), individual sex hormones showed limited evidence of mediating this relationship except for a weak effect through free estradiol. However, when researchers used a sophisticated statistical approach (partial least squares regression) to create an alcohol-related hormonal signature—characterized by lower SHBG and higher estradiol and testosterone—this hormonal pattern was associated with 25% increased breast cancer risk and mediated approximately 24% of the alcohol-breast cancer association. These findings suggest that alcohol increases breast cancer risk partly through a complex hormonal mechanism involving the interplay of multiple sex hormones rather than through individual hormones alone, providing new mechanistic insight into how alcohol consumption drives breast carcinogenesis in postmenopausal women and supporting recommendations to limit alcohol intake for breast cancer prevention.
2019
Environ Pollut
This study investigated how three endocrine-disrupting chemicals (BPA, BBP, and DEHP) affect estrogen receptor alpha (ERα) activity under normal and low-oxygen (hypoxic) conditions in breast and endometrial cancer cells. The researchers found that BPA and BBP activated ERα at specific concentrations, while DEHP did not, but all three chemicals enhanced ERα-mediated gene activity and decreased ERα protein levels under hypoxic conditions. BPA and BBP also affected hypoxia-related factors, decreasing hypoxia-inducible factor-1 activity while increasing VEGF (a blood vessel growth factor) secretion in breast cancer cells, whereas DEHP had different effects. The findings suggest that these endocrine disruptors can alter ERα regulation under low-oxygen conditions, which may influence disease processes since hypoxia is common in tumors and other pathological states.
2018
PLOS One
This study investigated how phthalates affect the growth of normal breast cells (MCF-10A) when grown alongside breast fibroblasts derived from tissue near estrogen receptor (ER) positive and negative breast cancers. The researchers found that only fibroblasts from ER-positive breast cancer tissue significantly stimulated breast cell proliferation, and when these co-cultures were exposed to estrogen or three phthalates (BBP, DBP, DEHP), cell growth increased significantly along with markers of cell division and estrogen receptor expression. The effects of phthalates on normal breast cells were similar to those of estrogen and depended on estrogen receptor activity, suggesting that phthalates act through hormone-mediated pathways. The study concludes that phthalates should be considered potential endocrine disruptors with breast cancer risk implications, even at low concentrations, particularly in the presence of estrogen-responsive tissue.
2011
J Steroid Biochem Mol Biol
Bisphenol A (BPA) is a widely produced chemical used in plastics and food container linings, with frequent human exposure due to its leaching into food and beverages. BPA, a known endocrine disruptor, was initially deemed a weak estrogen but has shown potency comparable to estradiol, a form of estrogen, shown to affect multiple hormonal pathways. Studies on rodents reveal adverse effects at levels below and at the current acceptable daily intake, raising concerns about human health impacts about concentration. BPA’s estrogenic effects highlight the importance of investigating BPA’s complex, widespread impacts on health.
2018
Reprod Toxicol
A developmental toxicology study exposed CD-1 mice to bisphenol S (BPS) at 2 or 200 μg/kg/day or ethinyl estradiol (EE2) at 0.01 or 1 μg/kg/day during pregnancy and lactation, then examined mammary glands of female offspring at three developmental stages (pre-puberty, puberty, and early adulthood) for growth parameters, histopathology, cell proliferation, and hormone receptor expression. The study revealed age- and dose-specific effects of BPS on mammary gland development that differed from both EE2 effects and previously reported bisphenol A (BPA) effects. These findings suggest that individual xenoestrogens—synthetic chemicals with hormonal activities—may have unique effects on mammary tissue development, supporting the hypothesis that endocrine-disrupting chemicals could contribute to breast diseases and dysfunction through disruption of normal mammary gland development, though each compound may act through distinct mechanisms.